Idexx laboratories announces fourth quarter and full year 2022 results

Achieves fourth quarter revenue growth of 3% reported and 7% organic, driven by cag diagnostics recurring revenue growth of 4% reported and 8% organic  solid growth supported by continued benefits from idexx execution drivers, including 13% year-over-year expansion of idexx's global premium instrument installed base delivers fourth quarter eps of $2.05, an increase of 8% as reported and 14% on a comparable basis, supported by operating margin expansion provides initial outlook for 2023 revenue of $3,590 million - $3,690 million, reflecting reported growth of 6.5% - 9.5% and organic growth of 7% - 10% estimates 2023 eps of $9.27 - $9.75, an increase of 16% - 21% as reported and 19% - 26% on a comparable basis, including ~ 10% growth benefit from lapping discrete r&d investments in 2022 westbrook, maine , feb. 6, 2023 /prnewswire/ -- idexx laboratories, inc. (nasdaq: idxx), a global leader in pet healthcare innovation, today announced fourth quarter and full year results, as well as an update on u.s. companion animal diagnostic trends. fourth quarter and full year results the company reports revenues of $829 million for the fourth quarter of 2022, an increase of 3% compared to the prior year period on a reported basis and 7% on an organic basis.
IDXX Ratings Summary
IDXX Quant Ranking